Scaling for growth
2023 Annual Report
Our purpose is to invest to extend and enhance human life
Watch video
Our team members are experts at what they do
Our people
A diversified portfolio of life science companies
Portfolio

To unlock the potential from truly innovative science to transform patients’ lives

We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses

Who we are

A diversified portfolio across clinical stages

Late-stage clinical companies
Late-stage clinical companies
Clinical companies
Clinical companies
Pre-clinical companies
Pre-clinical companies
Explore our portfolio

Making a positive contribution

We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.

Sustainability

Latest videos

Launching Beacon Therapeutics

| Video length 7:36

Scaling for growth

| Video length 09:28

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

| Video length 7:43

Syncona CEO Martin Murphy discusses Clade Series A financing

| Video length 10:16

Anaveon doses first patient

| Video length 6:18

Introduction to Richard Francis, Chief Executive of Purespring Therapeutics

| Video length 3:42

Introduction from Quell Therapeutics, CEO, Iain McGill

| Video length 5:38

Quell: the science and the unmet medical need for patients

| Video length 5:25

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

| Video length 4:25

Introducing Resolution Therapeutics

| Video length 11:28

Introduction to Purespring

| Video length 5:47

Syncona FY20: Martin Murphy discusses FY20 results

| Video length 6:15

Syncona FY20: Martin Murphy discusses the impact of COVID-19

| Video length 4:52

Syncona FY20: Martin Murphy discusses the outlook for Syncona

| Video length 2:53

Achilles doses first patient

| Video length 1:40

Gene Therapy explained

| Video length 3:11

Building Syncona’s Gene Therapy platform

| Video length 7:02

An introduction to Gene Therapy

| Video length 4:45
View all videos

Latest insights

Modality precision is the new precision in medicine

Taking a proactive approach to portfolio company sustainability

Launching Beacon Therapeutics

Leveraging the Syncona team for our next phase of growth

Good science must survive in challenging markets

Scaling for growth

Building a global leader in retinal gene therapy

Welcoming our first Windsor Fellowship intern to Syncona

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

Syncona CEO Martin Murphy discusses Clade Series A financing

Alex Hamilton on manufacturing in cell and gene therapy and the role of development partnerships

Ed Hodgkin provides his perspectives from a career in early-stage biotech

Encouraging diversity in the next generation of scientists

Anaveon doses first patient

Uniting against dementia with Alzheimer’s Society

Partnering with our charities

Marie Curie case study

Introduction to Richard Francis, Chief Executive of Purespring Therapeutics

View all insights and articles

Latest news

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

Syncona to Acquire Freeline Therapeutics

Syncona Half Year Results for the Period Ending 30 September 2023

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

OMass Therapeutics expands leadership team with the appointment of Melissa Faris as Chief Business Officer

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Resolution Therapeutics’ founders present clinical proof-of-concept for macrophage cell therapy in end-stage liver disease at AASLD

Autolus Therapeutics announces participation in upcoming conferences

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors

Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting

SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer

Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Freeline Announces Positive Initial Clinical Data

SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy

View all news
2023 Annual Report front cover

2023 Annual Report

Our Annual Report and Accounts 2023 provides an overview of our most recent financial year, as we continue to deliver on behalf of our stakeholders.

28.06.23 | pdf (4.25Mb)
Download

An expert multi-disciplinary team, attracting world-class talent

We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.

Our people

Investment team key facts

All as of 31 March 2023

14

Members of the investment team

200

Years of life science and investment expertise

79%

Investment team with PhDs

Search